Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11077344 | 0.85 | CA12 (0.56) | EPHX2NR1H4MAPTRAB9ACA12 | |
| SCHEMBL26491052 | 0.83 | CA12 (0.54) | EPHX2NR1H4MAPTRAB9ACA12 | |
| SCHEMBL13661999 | 0.83 | L3MBTL1 (0.73) | SRCMAPTRAB9ACA12CA1 | |
| SCHEMBL9610847 | 0.83 | SRC (0.49) | SRCRAB9AHDAC3HDAC4HDAC1 | |
| SCHEMBL8694779 | 0.82 | EPHX2 (0.59) | EPHX2NR1H4MAPTRAB9ACA12 | |
| SCHEMBL9791549 | 0.82 | CA1 (0.57) | SRCRAB9ACA1CA2HDAC3 | |
| SCHEMBL24350476 | 0.81 | L3MBTL1 (0.53) | EPHX2NR1H4MAPTCA12CA1 | |
| SCHEMBL8130459 | 0.81 | CA12 (0.53) | EPHX2NR1H4MAPTRAB9ACA12 | |
| SCHEMBL18227059 | 0.81 | CA12 (0.57) | EPHX2NR1H4MAPTRAB9ACA12 | |
| SCHEMBL6929655 | 0.81 | KMT2A (0.56) | SRCMAPTRAB9AHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752617-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-08-25 | — | — | US | disclosed |
| US-20190202819-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-07-04 | — | — | US | disclosed |
| US-10246440-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| EP-3233836-B1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RES & DEV (FR) | 2019-01-30 | — | — | EP | disclosed |
| US-20170342062-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
| EP-3233836-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | Galderma Research & Development (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097394-A1 | BICYCLIC SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097391-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246440-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) | RORA, RORB, RORC | EPHX2 1712/4885NR1H4 16/4885SRC 1523/4885 |
| US-20170342062-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | RORA, RORB, RORC | EPHX2 1726/4885NR1H4 16/4885SRC 1598/4885 |
| US-20190202819-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | RORA, RORB, RORC | EPHX2 1726/4885NR1H4 16/4885SRC 1598/4885 |
| US-10752617-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | RORA, RORB, RORC | EPHX2 1726/4885NR1H4 16/4885SRC 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.